In a report released today, Stefan Quenneville from Echelon Wealth Partners maintained a Buy rating on Cognetivity Neurosciences (CGNSF – Research Report), with a price target of C$0.90. The company’s shares closed last Monday at $0.23, close to its 52-week low of $0.16.
According to TipRanks.com, Quenneville is ranked #7795 out of 7950 analysts.
The word on The Street in general, suggests a Hold analyst consensus rating for Cognetivity Neurosciences.
Based on Cognetivity Neurosciences’ latest earnings release for the quarter ending October 31, the company reported a quarterly GAAP net loss of $6.04 million. In comparison, last year the company had a GAAP net loss of $95.94K.
Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CGNSF in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cognetivity Neurosciences Ltd is developing a platform technology comprising of a visual stimulus based diagnostic test and artificial intelligence tools to support the early detection and monitoring of cognitive impairment in neurodegenerative diseases, with initial emphasis on dementia in Alzheimer’s disease and mild cognitive impairment, a difficult-to-diagnose, “pre-dementia” condition.
Read More on CGNSF:
- 2 Stocks That Gave Five-Star Financial Blogger Nick Cox Skyrocketing Returns
- Infineon Technologies AG (IFNNF): New Buy Recommendation for This Technology Giant
- Marathon Oil (MRO) Receives a Hold from Morgan Stanley
- Antero Resources (AR) Gets a Hold Rating from Morgan Stanley
- Morgan Stanley Maintains a Sell Rating on Walgreens Boots Alliance (WBA)